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Abstract
Objective: Social support is acknowledged as important in cancer survivorship, but little is
known about change in support after cancer diagnosis and factors associated with this, particu-
larly in colorectal cancer. The CREW cohort study investigated social support up to 2 years fol-
lowing curative intent surgery for colorectal cancer.
Methods: A total of 871 adults recruited pre‐treatment from 29 UK centres 2010 to 2012
consented to follow‐up. Questionnaires at baseline, 3, 9, 15, and 24 months post‐surgery
included assessments of social support (Medical Outcomes Study‐Social Support Survey, MOS‐
SSS) and health‐related quality of life (HRQoL). Socio‐demographic, clinical and treatment details
were collected. Longitudinal analyses assessed social support over follow‐up, associations with
participant characteristics, and HRQoL.
Results: Around 20% were living alone and 30% without a partner. Perceived social support
declined in around 29% of participants, with 8% of these reporting very low levels overall from
baseline to 2 years (mean MOS‐SSS overall score < 40 on a scale from 0 to 100). Older age,
female gender, greater neighbourhood deprivation, presence of co‐morbidities, and rectal cancer
site were significantly associated with reductions in perceived support. Poorer HRQoL outcomes
(generic health/QoL, reduced wellbeing, anxiety, and depression) were significantly associated
with lower levels of social support.
Conclusions: Levels of social support decline following colorectal cancer diagnosis and treat-
ment in nearly a third of patients and are an important risk factor for recovery of HRQoL. Assess-
ment of support early on and throughout follow‐up would enable targeted interventions to
improve recovery, particularly in the more vulnerable patient groups at risk of poorer social
support.
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1 | BACKGROUND
Social support is widely regarded as beneficial to people living with
and beyond cancer, particularly for psychological wellbeing,1 and
has been proposed as an important aspect of recovery,2 as well as
in planning survivorship care.3 Higher levels of support have been
shown to be associated with better health outcomes and health‐
related quality of life (HRQoL) following cancer treatment, with most
studies in breast cancer.4,5 However, few studies have investigated the
role of social support in colorectal cancer, despite being the most com-
mon cancer type that affects both genders. Results from small cross‐sec-
tional studies in colorectal cancer have shown associations between
lower social support and poorer psychological wellbeing and HRQoL.6-8
Longitudinal studies showing similar associations are limited by short or
incomplete follow‐up (≤ 1 year) or no pre‐treatment baseline data.9-12
Furthermore, there is very little published evidence on changing
levels of social support following a cancer diagnosis. Studies in breast
cancer suggest that support levels decline following diagnosis and
treatment,13-16 although 1 study reported levels remaining moderately
high over 3 years' follow‐up.5 Limited evidence from other cancer sites
also varies; support levels were reported to be stable up to 1 year
follow‐up in a prostate cancer study (N = 134,17), but declined pre‐treat-
ment to post‐treatment in head and neck cancer (N = 3218). Longitudinal
data on social support in colorectal cancer are extremely sparse; a study
in China (N = 227) reported declining support up to 1 year following sur-
gery, particularly in women and those with a lower family income.19
Alternative supportive self‐management models for cancer after‐
care are being implemented in the UK, such as patient‐triggered fol-
low‐up whereby patients initiate contact if they experience symptoms
or have concerns. Compared with the routine follow‐up approach,
patients are likely to have less contact with health care professionals,
and therefore it is more important than ever to determine patterns
of social support following treatment. Identification at diagnosis of
individuals who might be at greater risk of poor and declining levels
of support as well as the potential effects of this on recovery of
HRQoL will help tailor management packages for these patients.
The UK ColoREctal Wellbeing study (CREW) is a large‐scale
cohort study investigating factors associated with recovery of health
and wellbeing following colorectal cancer. The domains of assessment
were informed by a conceptual framework of recovery following can-
cer diagnosis and treatment,2 which hypothesised that a number of
factors including social support would affect recovery. The main aim
of this paper was to describe patient‐reported social support pre‐sur-
gery up to 2 years' follow‐up, in particular to investigate any change
in support over time and which individuals were more likely to report
poorer levels of support. A secondary aim was to investigate associa-
tions between social support over follow‐up and HRQoL outcomes.
2 | METHODS
2.1 | Study design and participants
CREW is a multicentre, prospective cohort study of adults with non‐met-
astatic colorectal cancer. Details of eligibility criteria, recruitment
strategy, and sample size are provided elsewhere.20 In brief, eligible indi-
viduals were approached before primary surgery from 29UK cancer cen-
tres between November 2010 and March 2012. Written consent was
obtained, and baseline questionnaires completed prior to surgery when-
ever possible. Follow‐up questionnaires were completed at 3, 9, 15, and
24months post‐surgery (longer‐term follow‐up is ongoing). Socio‐demo-
graphic information was also collected at consent. Participants reported
whether they lived alone, and self‐reported co‐morbidities were
recorded from 3 months onwards; clinical and treatment details were
taken from medical notes. Ethical approval was granted by the UK NHS
NRES Committee South Central—Oxford B (REC ref: 10/H0605/31).
2.2 | Measures
Full details of the questionnaire measures used in the CREW study are
provided elsewhere.20 The measures presented in this paper are
described in brief:
The Index of Multiple Deprivation21 is the official measure of rel-
ative deprivation for small areas in England and uses postcodes to cal-
culate an overall deprivation score based on 7 weighted domains of
deprivation including income, employment, education, health, crime,
barriers to housing and services and living environment.
Availability of social support was assessed in various ways: partic-
ipants reported whether or not they lived alone, and number of close
friends and family. The MOS Social Support Survey (MOS‐SSS22) yields
an overall measure of social support (mean of all 19 items), subscales
representing emotional/informational support, tangible support, affec-
tionate support and positive social interaction (higher scores represent
greater support, range 0–100), and an individual item relating to the
extent to which participants feel they have “someone to do things with
to help you get your mind off things” (Appendix S1).
The EQ‐5D23 measures generic health status/QoL, comprising 5
domains (mobility, self‐care, usual activities, pain/discomfort, anxiety/
depression), each scored as none/some/severe problems, which can be
summarised overall as presence/absenceof problemson≥1of the domains.
The Personal Wellbeing Index—Adult (PWI‐A24) contains 8 items
of satisfaction corresponding to standard of living, health, achieving
in life, relationships, safety, community‐connectedness, future security,
and spirituality/religion. A higher overall score of wellbeing denotes
better wellbeing (range 0–100; < 70 represents reduced wellbeing).
Anxiety and depression were assessed using the State‐Trait
Anxiety Inventory (STAI25) and the Centre for Epidemiologic Studies
Depression Scale (CES‐D26). Higher scores indicate greater anxiety
and depression; ≥40 indicates clinical levels of anxiety27 (range
20–80); and ≥20 has been suggested to indicate clinical depression
for cancer patients (Katz et al, 2004,28 range 0–60).
2.3 | Statistical methods
Published guidance for missing items in subscales were applied where
available; otherwise, if ≥75% of items had been completed, mean
scores were imputed from completed items. MOS‐SSS scores were
calculated according to published guidelines; binary variables were also
created indicating whether a participant had responded “none” or “a
little of the time” to all items within a subscale (versus “some/most/
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all of the time”). The Index of Multiple Deprivation was categorised
into quintiles. Descriptive analyses summarised measures of social
support at each time‐point. A sensitivity analysis was performed
including only those questionnaires completed within specific
timeframes around the expected date; as this made very little differ-
ence to the results, all data were included for the analyses presented.
For longitudinal analyses, length of follow‐up was calculated
from surgery to date of questionnaire completion (or date question-
naire received in research office if unknown); timing of baseline
questionnaire (pre/post‐surgery) was adjusted for in all regression
models. Patterns of change in levels of social support from baseline
to 2 years were analysed using: (1) Generalised Estimating Equations
(GEE29) to assess mean levels of the individual domains of support
for the overall cohort over follow‐up, and (2) group‐based trajectory
analyses30 to investigate whether there were subgroups with distinct
levels of support from the MOS‐SSS overall social support score. In
brief, each individual participant has an observed trajectory; the
modelling technique sorts the individual trajectories into clusters
according to mean‐level changes in the outcome variable and rank
orders these groups over follow‐up. The optimal number of distinct
trajectories was determined using the Bayesian information criterion
(BIC)31 to compare model fit (change in BIC >10 supports the more
complex model), while aiming to avoid trajectories containing few
individuals. The shape of each trajectory was assessed to determine
whether it was best described by a linear, quadratic, or cubic func-
tion according to the significance of each term. Estimated propor-
tions of participants within each trajectory were obtained, with
95% confidence intervals (CI). The estimated trajectory groups were
plotted according to mean scores of MOS‐SSS overall social support
score at each time‐point.
Predictors of group membership for the MOS‐SSS overall social
support score were investigated by fitting baseline participant charac-
teristics (socio‐demographic and clinical) in the trajectory models. Fre-
quencies of participant characteristics in each group were compared
with the reference group (best levels of support). Factors found to be
significant or borderline significant (P < 0.1) from univariate analyses
were modelled together, and only those which remained statistically
significant for at least 1 of the group comparisons were retained in
the final prediction models.
Associations between social support and HRQoL outcomes from
baseline to 24 months (generic health/QoL measured by the EQ‐5D,
personal wellbeing, clinical levels of anxiety and clinical levels of
depression, all fitted as binary variables) were assessed in separate
GEE models for each measure of social support (fitted as a time‐
dependent variable to allow for repeated measures over follow‐up),
adjusting for baseline participant characteristics. Odds ratios (OR)
were used to describe the relative increase in odds of eachHRQoL binary
outcome with a unit increase in the measure of social support for MOS‐
SSS overall social support score, and for each category compared with
the reference category for the binary social support variables. The poten-
tial for a random effect of recruiting site was explored in the GEE models
for HRQOL outcomes and was found to be negligible.
The Wald test was used to assess significance in all regression
analyses. Statistical analyses were done using Stata version 14 and
IBM Statistics SPSS version 24.
3 | RESULTS
3.1 | Characteristics of the sample
A total of 857 participants consented to follow‐up excluding 15 who
withdrew at baseline. Response rates were 89% at baseline, 84% at
3 months, 82% at 9 months, 80% at 15 months, and 74% at 24 months.
Baseline questionnaires were completed prior to primary surgery in
70% of participants, and within 3 months after surgery by a further
26%; reasons for post‐surgical baseline questionnaires included admis-
sion for emergency surgery. Participants with and without a 24‐month
questionnaire were broadly similar in terms of demographic and clinical
characteristics, with similar levels of social support at baseline. The
mean age of participants at study entry was 68 years, with 60% male.
The sample comprised 65% colon and 35% rectal cancer, disease stage
was 14% Duke's A, 53% Duke's B, and 32% Duke's C. By 2 years, 79
participants had experienced a recurrence, 65 had died, and 105 had
withdrawn for reasons such as a deterioration in health, co‐morbid-
ities, significant life events, or that the participant felt the questions
were no longer relevant as they had recovered from their cancer. Full
details of participants are described elsewhere.32
3.2 | Levels of social support from baseline to 2 years
after surgery
At baseline, 70.6% of participants were married or living with a partner.
Around 20% of participants reported that they lived alone (21.3% at
3 months and 23.5% at 24 months). The median number of close
friends and family reported at baseline was 6 and 7, respectively, and
remained stable over follow‐up. At baseline, 7.8% of participants
reported that they had “someone to help them get their mind off
things” none/a little of the time, increasing to 17.3% at 2 years
(Table 1). Proportions reporting none/a little of the time to all items
within the MOS‐SSS subscales at baseline and 2 years were 2.5%
and 10.1% for emotional/informational support, 5.1% and 12.4% for
tangible support, 4.5% and 12.9% for affectionate support, and 6.5%
and 12.4% for positive social interaction. All of the MOS‐SSS subscales
and the overall measure of social support indicated a statistically signif-
icant decrease in support over follow‐up (P < 0.001 for all MOS‐SSS
scales) (Table 1), although the absolute change in mean scores was
small for some domains, bordering on clinically important differences
(effect size = 0.4 for change in overall social support score from base-
line to 2 years).
The optimal number of distinct trajectories identified for the
MOS‐SSS overall social support score over follow‐up was 4, based
on assessing the change in BIC (83.19 from 3 groups to 4) and esti-
mated number of participants in the smallest group (8%). The 4 groups
were as follows: (1) very high and constant levels of support, with an
estimated 33.9% (95%CI 28.4–39.3%) of participants, (2) good and
constant levels of support, 36.9% (95%CI 31.9–41.9%), (3) mid and
declining levels of support, 21.2% (95%CI 17.3–25.1%), and (4) low
and declining levels of support, 8.0% (95%CI 5.4–10.6%). The patterns
of the groups are shown in Figure 1, which illustrates the decrease in
mean levels of overall social support for Groups 3 and 4.
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3.3 | Associations between baseline participant
characteristics and levels of social support over
follow‐up
Participants estimated to be in Group 3 (mid/declining support) were
significantly older (52% aged >70) and with a greater proportion of
women (47%) compared with Group 1 (very high/constant support;
39% aged >70 and 36% women, P = 0.046 for both) (Table 2). For
Group 4 (low/declining support), participants were significantly more
likely to have higher neighbourhood deprivation (52% in fourth or fifth
quintiles versus 37% for Group 1; P = 0.049), co‐morbidities (84% ver-
sus 69%, P = 0.021), and to have had rectal rather than colon cancer
(42% versus 35%, P = 0.013). These factors remained statistically sig-
nificant when included together in the final trajectory model for the
MOS‐SSS overall score (Table 2). Odds ratios for trajectory group
membership according to each participant characteristic in the final
model are shown in Table A1 (Appendix). There were no independent
significant associations between social support trajectory and Dukes
stage, neoadjuvant or adjuvant therapy, or stoma, after allowing for
the factors already identified, and no significant differences in partici-
pant characteristics between Groups 1 and 2, who had fairly constant
levels of support over the 2 years.
3.4 | Associations between levels of social support
and HRQoL outcomes
Poorer HRQoL outcomes within 2 years were significantly associated
with lower levels of social support throughout follow‐up, adjusting
for baseline participant characteristics (Table 3). Poorer generic
health/HRQoL (problems on ≥1 EQ‐5D domains) was significantly
associated with lower overall support (P < 0.001), lack of affectionate
support (P = 0.024), lack of positive social interaction (P < 0.001), and
TABLE 1 Levels of social support from baseline to 2 years
Measure of social support
Baseline 3 months 9 months 15 months 24 months
N = 756 N = 668 N = 623 N = 579 N = 514
Living alone N/A
No 511 (76.5%) 469 (75.3%) 397 (65.6%) 365 (71.0%)
Yes 142 (21.3%) 142 (22.8%) 124 (21.4%) 121 (23.5%)
Unknown 15 (2.2%) 12 (1.9%) 58 (10.0%) 28 (5.4%)
Domestic status
Married/living with partner 534 (70.6%) 478 (71.6%) 437 (70.1%) 372 (64.2%) 340 (66.1%)
Single/widowed/divorced/separated 218 (28.8%) 185 (27.7%) 185 (29.7%) 160 (27.6%) 149 (29.0%)
Unknown 4 (0.5%) 5 (0.7%) 1 (0.2%) 47 (8.1%) 25 (4.9%)
Number of close friends
Median (IQR) 6 (3–10) 5 (3–10) 5 (3–8) 5 (3–10) 5 (3–9.75)
Number of close family members
Median (IQR) 7 (4–10) 5 (4–10) 6 (3–10) 6 (3–10) 6 (4–10)
Medical Outcomes Study (MOS) Social Support Surveya
Overall social support
Mean (SD); 80.9 (20.9) 77.9 (23.2) 74.1 (25.4) 74.5 (26.2) 72.0 (27.3)
Emotional/informational support
Mean (SD);
Number (%) responding none/a
little of the time to all items
78.3 (23.5)
20/753 (2.5%)
75.6 (25.2)
32/663 (4.8%)
71.3 (27.7)
39/618 (6.3%)
71.1 (29.0)
41/534 (7.7%)
68.8 (30.1)
51/504 (10.1%)
Tangible support
Mean (SD);
Number (%) responding none/a
little of the time to all items
82.8 (25.9)
38/752 (5.1%)
80.2 (28.4)
46/660 (7.0%)
75.3 (32.3)
72/614 (11.7%)
76.4 (32.1)
60/536 (11.2%)
74.1 (32.8)
62/500 (12.4%)
Affectionate support
Mean (SD);
Number (%) responding none/a
little of the time to all items
87.1 (24.1)
34/748 (4.5%)
83.7 (26.9)
44/661 (6.7%)
80.1 (29.7)
62/618 (10.0%)
80.6 (30.1)
56/534 (10.5%)
77.8 (31.6)
65/503 (12.9%)
Positive social interaction
Mean (SD);
Number (%) responding none/a
little of the time to all items
79.6 (26.4)
48/743 (6.5%)
76.3 (28.2)
61/655 (9.3%)
74.5 (29.7)
76/617 (12.3%)
75.7 (29.4)
63/535 (11.8%)
72.7 (30.3)
62/500 (12.4%)
Someone to do things with to help you get your mind off things
Number (%) responding none/a
little of the time
56/719 (7.8%) 74/617 (12.0%) 92/580 (15.9%) 78/504 (15.5%) 85/492 (17.3%)
N/A, not available (not asked on questionnaire); SD, standard deviation.
aAll MOS subscales can range from 0 to 100, with higher scores indicating greater support.
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FIGURE 1 Estimated trajectories from
baseline to 2 years' follow‐up for MOS‐SSS
overall social support index (N = 808 with data
available)
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TABLE 2 Associations between baseline characteristics and estimated trajectories of social support up to 2 years (odd ratio data are shown in
Table A1)
Baseline characteristics
Trajectories of MOS‐SSS overall social support
Group 1 (very high and
constant)
Group 2 (good and
constant)
Group 3 (mid and
declining)
Group 4 = (low and
declining)
N = 268 (%) N = 308 (%) N = 172 (%) N = 60 (%)
Age Ref. group P = 0.392 P = 0.046 P = 0.460
≤60 39 (14.5) 73 (23.8) 33 (19.2) 14 (23.3)
61–70 126 (47.0) 113 (36.8) 50 (29.1) 16 (26.7)
71–80 83 (31.0) 86 (28.1) 61 (35.5) 21 (35.0)
>80 20 (7.5) 35 (11.4) 28 (16.3) 9 (15.0)
Unknown 0 1 0 0
Gender Ref. group P = 0.423 P = 0.046 P = 0.278
Male 171 (63.8) 184 (59.7) 91 (52.9) 35 (58.3)
Female 97 (36.2) 124 (40.3) 81 (47.1) 25 (41.7)
Neighbourhood deprivation quintile Ref. group P = 0.138 P = 0.114 P = 0.049
1st (least deprived) 64 (24.2) 59 (19.7) 29 (17.3) 8 (13.3)
2nd 48 (18.2) 69 (23.0) 39 (23.2) 10 (16.7)
3rd 55 (20.8) 58 (19.3) 30 (17.9) 11 (18.3)
4th 50 (18.9) 46 (15.3) 34 (20.2) 20 (33.3)
5th (most deprived) 47 (17.8) 68 (22.7) 36 (21.4) 11 (18.3)
Unknown 4 8 4 0
Any co‐morbidities Ref. group P = 0.176 P = 0.822 P = 0.021
No 70 (31.5) 65 (26.2) 41 (28.7) 7 (15.6)
Yes 152 (68.5) 183 (73.8) 102 (71.3) 38 (84.4)
Unknowna 46 60 29 15
Tumour site Ref. group P = 0.190 P = 0.995 P = 0.013
Colon 175 (65.3) 194 (63.6) 114 (66.3) 35 (58.3)
Rectum 93 (34.7) 111 (36.4) 58 (33.7) 25 (41.7)
Unknown 0 3 0 0
P‐values from Wald test comparing each Group with Group 1 (reference group) in multiple regression model including all variables in table and adjusting for
pre/post‐surgery baseline.
aCo‐morbidities reported on 3‐month questionnaire.
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not having “someone to take their mind off things” (P = 0.008).
Reduced personal wellbeing and high levels of depression were con-
sistently significantly associated with lower levels of support
(P < 0.001 for all MOS‐SSS domains). High levels of anxiety were
significantly associated with lower levels of support (P < 0.001 for
all domains except emotional/informational support where
P = 0.018). Lack of positive social interaction appeared to have the
greatest effect on the outcomes: odds ratio 2.55 (95%CI
1.61–4.04) for poorer generic health/QoL, 5.43 (3.79–7.79) for
reduced personal wellbeing, 4.27 (2.93–6.22) for high levels of anx-
iety. and 5.65 (3.93–8.14) for high levels of depression.
4 | DISCUSSION
4.1 | Levels of social support
Our study found that, whilst the proportion of participants living
alone and numbers of family and friends remained stable up to
2 years' follow‐up after surgery for colorectal cancer, levels of per-
ceived social support significantly reduced across all the MOS‐SSS
domains in the sample as a whole. For the overall sample, the pro-
portion of participants reporting a lack of support in the individual
domains more than doubled from baseline to 2 years. MOS‐SSS
domain scores were lower than reported in a breast cancer cohort
of similar age to the CREW sample.33 An overall lack of perceived
social support was also reported in a cross‐sectional study of mixed
cancer types in Korea, where levels of support were lower for colo-
rectal cancer than for other cancers.8 In addition to considering the
overall cohort, we also found distinct subgroups of participants,
some of which had relatively stable levels of support over time (an
estimated 71%), and others with poorer and declining support
(21% mid/declining support and 8% low/declining support).
Most of the literature relating to change in social support following
cancer diagnosis and treatment is in breast cancer, and to our knowl-
edge no studies have described distinct subgroups. A study of colorec-
tal cancer survivors in China (N = 227) reported levels of social support
that were stable from pre‐surgery baseline to 3 months' follow‐up,
declined up to 6 months, and remained low up to 1 year following sur-
gery.19 A number of studies in different countries have reported
decreased social support within the first 2 years following diagnosis
and treatment for breast cancer, with some reporting changes as early
as 6 months.13-15 Leung et al5 reported stability in social support rat-
ings up to 3 years post‐diagnosis, although the number of women with
3 year data was low (N = 124 of the 412 in their study), and so they
may have been unrepresentative. The cause of reduced perceived
social support following cancer diagnosis and treatment is unclear.
Eom et al8 suggested that prolonged caregiving burden and expecta-
tions of patients' recovery following cancer treatment may lead to a
reduction in support from family and loved ones. In addition, individ-
uals providing the support might not be aware what type of support
is needed or indeed if it is still required as the post‐treatment time
progresses, which suggests that carers themselves might need guid-
ance on how best to provide support over time. Also, with patterns
of follow‐up changing to earlier discharge, and hence less contact
with health care professionals, this may have an impact on people's
perception of levels of social support. It is therefore important to
identify at diagnosis those most likely to have poorer and declining
support so that relevant interventions can be put into place at an
early stage.
4.2 | Associations between participant
characteristics and levels of social support
Our findings suggested that participants with lower and declining
levels of social support were more likely to be older, female, with
TABLE 3 Associations between social support and HRQoL outcomes up to 2 years following surgery
Measure of social support from MOS‐SSS
Poorer generic health/
QoL (EQ‐5Da)
Reduced personal
wellbeing (PWI <70)
Clinical level anxiety
(STAI ≥ 40)
Clinical level depression
(CES‐D ≥ 20)
ORc (95%CI), P‐value ORc (95%CI), P‐value ORc (95%CI), P‐value ORc (95%CI), P‐value
Lower overall social support (total score)b P < 0.001 P < 0.001 P < 0.001 P < 0.001
1.01 (1.01,1.02) 1.04 (1.03,1.04) 1.02 (1.02,1.03) 1.03 (1.03,1.04)
Emotional/informational support P = 0.064 P < 0.001 P = 0.018 P < 0.001
None/a little vs some/most/all of the time 1.64 (0.97,2.76) 3.38 (2.25,5.09) 1.64 (1.09,2.47) 2.70 (1.73,4.22)
Tangible support P = 0.170 P < 0.001 P < 0.001 P < 0.001
None/a little vs some/most/all of the time 1.37 (0.87,2.16) 2.90 (2.00,4.20) 1.89 (1.33,2.70) 3.24 (2.24,4.69)
Affectionate support P = 0.024 P < 0.001 P < 0.001 P < 0.001
None/a little vs some/most/all of the time 1.70 (1.07,2.71) 4.81 (3.26,7.11) 2.83 (1.88,4.26) 5.77 (4.00,8.32)
Positive social interaction P < 0.001 P < 0.001 P < 0.001 P < 0.001
None/a little vs some/most/all of the time 2.55 (1.61,4.04) 5.43 (3.79,7.79) 4.27 (2.93,6.22) 5.65 (3.93,8.14)
Someone to do things with to help you get
your mind off things
P = 0.008 P < 0.001 P < 0.001 P < 0.001
None/a little vs some/most/all of the time 1.68 (1.14,2.48) 3.71 (2.71,5.07) 2.92 (2.11,4.03) 4.04 (2.87,5.69)
CI, confidence interval; OR, odds ratio.
aProblems on ≥1 of the 5 EQ‐5D domains.
bLower scores for MOS‐SSS overall social support indicate lower levels of support.
cAdjusting for baseline age, gender, deprivation, co‐morbidities, and tumour site.
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greater neighbourhood deprivation, to have co‐morbidities and rectal
cancer. Those who could be regarded as most vulnerable and in need
of support from others are those who might have fewer opportunities
to interact with others or perceive less support available. Our findings
are mostly consistent with previous findings, particularly with respect
to poorer social support and lower socio‐economic status.8 A study of
mixed cancer types in the US (including 380 colorectal cancer
patients) reported higher perceived social support in those with ade-
quate financial resources but no association with age or gender.3
Published evidence of gender differences in perceived social support
varies. LeMasters et al34 reported lower levels of emotional support
for women compared with men in around 2000 colorectal cancer
patients in the USA, but a study of mixed cancer types in South
Korea reported lower levels of perceived social support for men,
although cultural differences may partly explain this finding.8 We
found 2 clinical factors associated with poorer social support over
follow‐up: having co‐morbidities and a stoma. Co‐morbidities have
been shown to adversely affect HRQoL following cancer35 and
may reduce social interactions, although conversely may increase
support from health care professionals. Having a stoma has been
reported as reducing participation in social activities and causing dif-
ficulties in relationships for colorectal cancer patients.36 Although we
did not find an independent association between stoma and poorer
perceived social support, participants with rectal cancer, where
stomas are more common, reported poorer support compared with
colon cancer.
4.3 | Associations between levels of social support
and HRQoL outcomes
Our findings confirmed published evidence that poorer social sup-
port is significantly associated with poorer HRQoL outcomes in
colorectal cancer (independent of demographic and clinical fac-
tors).11,35 A cohort study described a link between social support
pre‐surgery for colorectal cancer and HRQoL outcomes including
pain, fatigue, and social functioning at 12 months, although only
65% of the participants had follow‐up data and were different from
those enrolled at baseline in a number of ways.9 Others have
explored social networks, e.g., Sapp et al10 focused on colorectal
cancer patients' social ties (number and frequency of contact)
rather than perceived support and quality, and demonstrated the
importance of social ties in maintaining or improving HRQoL, par-
ticularly mental health. The relationship between social support
and depression is interdependent in that, just as anxiety and
depression are related to a lower perception and availability of
social support, poor social support in turn can lead to greater sus-
ceptibility to depression and anxiety. So, it is perhaps unsurprising
that social support has been consistently shown to have a strong
association with mental health in cancer survivors, including colo-
rectal cancer.6-8,10,12,37 Improved outcomes for patients with
greater social support can also be interpreted within the context
of promoting health care behaviours,10 such as adherence with fol-
low‐up,38 and timing of commencing adjuvant chemotherapy39 as
well as lifestyle factors.40
4.4 | Strengths and limitations of the study
Strengths of our study include the size and representative nature of
the CREW sample. Loss to follow‐up is generally inevitable in large
cohort studies; however, response rates remained high up to 2 years
(74%). The longitudinal design provided the opportunity to carry out
repeated assessments at several time‐points evaluating a wide range
of measures including HRQoL outcomes and a range of psychosocial
domains including social support. The current paper reports 2 years'
follow‐up, but data collection up to 5 years is ongoing, enabling further
investigations into longer‐term outcomes following colorectal cancer
treatment. The study also has the merits of including pre‐treatment
baseline assessments. Regarding the assessment of social support,
although we assessed actual and perceived support using a number
of measures, we did not investigate details of social networks, includ-
ing frequency of social ties and quality of support received from others
that have been considered in previous studies,10,16 or satisfaction with
support.7 In addition, our study might have benefitted from measuring
caregivers' perspectives on social support offered.
4.5 | Clinical implications
Our study has important implications for how patients can be optimally
supported throughout the disease and survivorship pathway to facili-
tate better recovery and outcomes. Assessments of levels of support
at diagnosis in particular and throughout treatment and follow‐up
would enable health care providers to identify vulnerable patients
and put interventions in place to increase support from other sources
where needed. This might involve signposting to support groups, invi-
tations to health and wellbeing events, increasing patients' confidence
in seeking and accepting support from others, and interventions to
support carers. Our findings highlight the importance of asking about
perceived levels of support; it cannot be assumed that for individuals
who have a wide circle of friends and family, there is naturally a per-
ception of high levels of support available to them. Health care profes-
sionals could ask patients to identify who they feel they can turn to for
help or support when then need it. In addition, in view of our findings,
this conversation should not just take place at diagnosis but be re‐vis-
ited throughout follow‐up.
5 | CONCLUSIONS
A substantial proportion of people report poor and reduced social sup-
port following diagnosis and treatment for colorectal cancer. Social
support is an important risk factor for recovery and HRQoL outcomes
in colorectal cancer, particularly mental health. Vulnerable patients
such as older people, those living in more deprived areas, and those
with co‐morbidities have less social support and, therefore, need more
targeted professional support throughout their care, with social sup-
port implemented from the point of diagnosis as part of a holistic
approach to health care provision.
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